Name: Dandruff and Seborrheic Dermatitis: A Yeast-and-Sebum Problem, Not a Dry Scalp
Creator: Realised
Published: 2026-06-01

Summary

Dandruff and seborrheic dermatitis are not a dry-scalp or a hygiene problem; they are a chronic inflammatory response to Malassezia yeast feeding on your scalp's sebum, so the move that actually works is to control the yeast with a proven antifungal shampoo (ketoconazole, zinc pyrithione, selenium sulfide, or ciclopirox) used on a maintenance cadence, while resisting the intuitive but counterproductive "my scalp is dry, add oil" response, since oleic-rich oils like olive oil can feed the very lipophilic yeast driving the flaking (coconut oil is the instructive exception — its lauric acid is po

Why Moderate

Moderate Evidence because the entry's spine — the Malassezia-and-sebum mechanism and antifungal-shampoo efficacy — rests on multiple RCTs and an independent Cochrane systematic review, which is solid, but the review itself downgrades the trials for short follow-up (rarely beyond 4 weeks) and finds no clear within-class winner, and a large share of the foundational literature is manufacturer-affiliated. The "oils feed the yeast and backfire" applied claim is weaker still: strong mechanistic and ecological grounding, but no head-to-head trial, so it rests on mechanism plus dermatology consensus.

NOT Strong because the marquee efficacy trials are short and mostly industry-funded, the within-class superiority claims don't replicate cleanly, and the practically important oils-backfire guidance has no RCT base.

NOT Emerging because the core mechanism and the antifungal-beats-placebo finding are well-established and independently confirmed, and the chronic-not-curable framing is uncontested clinical consensus.

The per-sub-area split (read this, not just the headline):
• The Malassezia-and-sebum mechanism: Strong-to-Moderate — seminal, widely corroborated, but largely industry-origin.
• Antifungal-shampoo efficacy vs placebo: Strong-to-Moderate — multiple RCTs plus independent Cochrane confirmation, downgraded for short follow-up.
• Within-class superiority (which agent is best): Emerging — no clear winner; sponsor-favouring framing.
• Oils feed the yeast / backfire: Emerging — solid mechanism, no RCT; present as caution, not proven harm.
• Chronic-relapsing, control-not-cure: Strong — uncontested consensus.

Practical takeaway

The framing to hold: this is a chronic condition you keep in check by controlling the yeast, not a dryness you cure by moisturising. Lead with a proven antifungal shampoo, use it on a maintenance cadence, and avoid the intuitive oil-the-scalp response.

Use a proven antifungal shampoo (the high-yield, evidence-backed lever).
• The agents with the best evidence are ketoconazole (often 1–2%), zinc pyrithione, selenium sulfide, and ciclopirox. The Cochrane review found no clear within-class winner, so the practical rule is: pick one that works for you and rotate if it stops working.
• Use it as directed and, crucially, leave it on the scalp for a few minutes before rinsing so the active has contact time, rather than rinsing immediately like a regular shampoo.
• For the face and chest (where seborrheic dermatitis also shows up), the same antifungal logic applies, but route facial and more severe involvement to a clinician rather than improvising.

Treat it as maintenance, not a one-off.
• Expect to keep using the shampoo on an ongoing cadence — often a few times a week during a flare, then dropping to a maintenance frequency (for example once or twice weekly) to keep it controlled. The exact cadence is individual.
• Plan for relapse if you stop. That is the biology, not a failure of the product. The honest expectation is durable control, not permanent clearing.

Avoid the oil-the-scalp trap.
• Resist the "my scalp is dry, I'll add oil / a hot-oil treatment" response. On a seborrheic scalp, heavy oleic-rich occlusive oils (olive oil is the clearest example) can feed the lipophilic yeast and often backfire. Coconut oil is the exception on substrate grounds — its lauric acid is poor-to-inhibitory fuel for the yeast — but that does not make it a treatment: there is no RCT that coconut oil helps dandruff, heavy occlusion can still be unhelpful, and the proven lever remains the antifungal shampoo.
• This is the single most common self-inflicted error in this condition, because the dry-scalp story is so intuitive. If you are genuinely unsure whether you have dry scalp or seborrheic dermatitis, the greasy/yellowish scale, the location (oily, sebum-dense areas), and the response to an antifungal shampoo point to seborrheic dermatitis.

Don't over-correct into "never wash, never touch it."
• This is not a hygiene problem, so neither aggressive scrubbing nor washing-avoidance is the lever. Regular gentle washing with the medicated shampoo is fine and useful; it is the active, not the act of washing, that does the work.
• General barrier-supporting and minimalist-skincare reasoning (gentle products, less is more) is owned by evidence_based_minimal_skincare; route there rather than re-deriving it here.

Know when it isn't seborrheic dermatitis.
• If the picture doesn't fit (well-demarcated thick silvery plaques suggest psoriasis; intensely itchy barrier-driven rash suggests eczema; facial redness and flushing suggests rosacea), or if it doesn't respond to a reasonable antifungal trial, see a clinician for diagnosis. Those distinctions are owned by their own entries.

Evidence detail

Why This Entry Exists

The flaking on your scalp comes with two confident, opposite stories, and both lead you wrong. One says it is a dry scalp that needs more moisture, so you reach for oils, heavier conditioners, and a coconut-oil treatment. The other says it is poor hygiene, so you scrub harder or wash more, or you swing the other way and wash less because someone told you washing strips your scalp. Neither story matches the biology. Seborrheic dermatitis and its milder form, dandruff, are an inflammatory reaction to Malassezia, a lipid-loving yeast that lives on everyone's scalp and feeds on sebum. The scalp here is usually oily, not dry, and the problem is not dirt. It is the yeast plus your sebum plus your individual sensitivity to the byproducts the yeast generates.

That changes the whole approach. The intuitive "it's dry, add oil" response is the seductive trap, because Malassezia is lipophilic and cannot make its own long-chain fatty acids, so it metabolises the longer-chain lipids you apply. Oleic-rich occlusive oils like olive oil can hand the yeast more of exactly what it eats; coconut oil is the exception, because its dominant lauric acid is a medium-chain fat that lab studies find poor-to-inhibitory for the yeast rather than good fuel. Meanwhile the genuinely effective treatments are antifungal shampoos, and that part of the story is well-established: multiple randomised trials and an independent Cochrane review confirm they beat placebo. The honest frame is control-the-yeast, on a maintenance cadence, expecting relapse if you stop, not moisturise-the-scalp-and-fix-it-forever.

What bad advice this protects against, in all directions:
• "Your scalp is dry, add oil / do an oil treatment" → can backfire. Malassezia is lipid-dependent and metabolises applied longer-chain fatty acids, so occlusive oiling with an oleic-rich oil (olive oil is high in oleic acid) on a seborrheic-dermatitis scalp may feed the yeast rather than soothe it. Coconut oil is the instructive exception: it is roughly half lauric acid, a medium-chain fat that lab studies find growth-inhibitory against Malassezia, so coconut specifically is not the substrate worry (even if heavy occlusion is still unlikely to help). Dry scalp is a real, separate thing that does benefit from moisture; the error is misclassifying seborrheic dermatitis as dry scalp.
• "It's poor hygiene / just wash more (or wash less)" → misses the point. This is not a dirt problem and not a wash-frequency problem; it is a yeast-and-sebum-and-sensitivity problem. Washing with a plain shampoo more often does not address the Malassezia load the way a medicated antifungal does.
• "Get the right shampoo once and you're cured" → overshoots. Seborrheic dermatitis is chronic and relapsing. Antifungal shampoos control it; stop using them and it tends to come back. Set the expectation of ongoing maintenance, not a cure.
• "All oils are bad, never put anything on your scalp" → over-corrects. The lipophilic mechanism is solid, but not every lipid is a good substrate — the medium-chain lauric acid that dominates coconut oil is actually growth-inhibitory against Malassezia in lab studies — and there is no trial proving "coconut oil worsens seborrheic dermatitis." The honest line is "heavy oleic-rich occlusive oils (e.g. olive oil) can feed the yeast and often backfire," framed as mechanistically-grounded caution, not proven harm.

This entry owns **the Malassezia mechanism, the genuinely-effective antifungal shampoos, the oils-can-feed-the-yeast correction, and the chronic-but-manageable framing**. It defers general skincare and barrier reasoning to evidence_based_minimal_skincare, and the acne, rosacea, and eczema distinctions to those entries.

Evidence

Organised by sub-area, tier signal inline. The mechanism and the antifungal-shampoo efficacy are solid; the "oils backfire" applied claim is the softer, mechanism-plus-consensus part. Read the tiers, not just the thesis.

Mechanism — the three-factor model (Strong-to-Moderate on the science, with a funding caveat).

**1. Dandruff and seborrheic dermatitis share a three-factor etiology: Malassezia yeast, sebaceous lipids, and individual susceptibility.** Malassezia lipases hydrolyse sebum triglycerides into free fatty acids; the saturated ones are consumed and the unsaturated ones, especially oleic acid, accumulate and irritate the scalp, driving inflammation and hyperproliferation (the visible flaking). This is the foundational mechanistic frame and it is widely cited. (DeAngelis YM, Gemmer CM, Kaczvinsky JR, Kenneally DC, Schwartz JR, Dawson TL Jr. "Three Etiologic Facets of Dandruff and Seborrheic Dermatitis: Malassezia Fungi, Sebaceous Lipids, and Individual Sensitivity." J Investig Dermatol Symp Proc. 2005;10(3):295–297. Strong-to-Moderate — seminal and widely corroborated, but a symposium narrative synthesis, not an experimental trial. BOTH-WAYS: the authors were Procter & Gamble Beauty scientists, makers of Head & Shoulders, and much of the foundational dandruff-mechanism literature is P&G-affiliated, so weigh accordingly even though independent groups corroborate it.)

2. Individual susceptibility is real and partly independent of yeast count. Applying oleic acid directly to the scalp induced dandruff-like flaking in susceptible subjects but not in non-susceptible ones, and the flaking occurred even without Malassezia present, which means the problem is a sensitivity to the fatty-acid byproducts breaching an impaired stratum corneum, not simply how much yeast is present. (Mechanistic work synthesised in DeAngelis 2005 and corroborating reviews; the barrier-breach framing — dandruff/seborrheic dermatitis result from scalp barrier penetration by Malassezia metabolites, particularly free fatty acids — reported in a J Am Acad Dermatol letter, 2004. Moderate — controlled human application studies; supports the "not just hygiene or yeast count" nuance. BOTH-WAYS: same P&G-affiliated mechanistic program, same industry-origin caveat.)

**3. Malassezia is lipid-dependent and feeds on longer-chain fatty acids — the basis for the "oleic-rich oils can feed the yeast" caution, with medium-chain fats as the exception.** Malassezia cannot synthesise its own long-chain fatty acids and favours longer-chain substrate, especially oleic acid (C18:1), which is why an oily scalp and oleic-rich applied oils such as olive oil provide fuel. The instructive exception is coconut oil: it is dominated by lauric acid (C12, a medium-chain fatty acid), which lab studies report as growth-inhibitory rather than a good substrate, so coconut specifically is the wrong poster child for "oils feed the yeast." (Genus-wide comparative genomics of Malassezia delineating its physiology and niche adaptation, and reviews on Malassezia lipases and the in-vitro activity of medium-chain fatty acids including lauric acid, e.g. "Skin Commensal Fungus Malassezia and Its Lipases," 2022. Moderate for the lipid-dependence mechanism; the specific clinical claim "oleic-rich oils worsen seborrheic dermatitis" is Emerging — mechanism plus dermatology-practitioner consensus, not RCT-confirmed. Genomics and lipase work is largely academic; the consumer "don't oil your seborrheic scalp" guidance comes mostly from dermatology clinics, not trials.)

Treatment — antifungal shampoos genuinely work (Strong-to-Moderate, mostly manufacturer-sponsored).

4. Ketoconazole 2% shampoo beats placebo and is modestly superior to zinc pyrithione 1%. In a multicenter randomised trial in severe dandruff and seborrheic dermatitis (171 on ketoconazole versus 160 on zinc pyrithione), ketoconazole produced 73% improvement in total dandruff severity at week 4 versus 67% for zinc pyrithione (p<0.02), with lower recurrence and better overall clearing (p=0.004). (Pierard-Franchimont C, et al. "A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis." Skin Pharmacol Appl Skin Physiol. 2002;15(6):434–441, PMID 12476017. Strong-to-Moderate — large multicenter head-to-head RCT. BOTH-WAYS: antifungal-shampoo trials are predominantly manufacturer-sponsored — Janssen for ketoconazole, P&G for zinc pyrithione — and a comparator-favouring framing tends to reflect the sponsor.)

5. Independent grading confirms the class works, but finds no clear within-class winner and short follow-up. A Cochrane systematic review found ketoconazole and ciclopirox have moderate-certainty evidence for symptom reduction versus placebo, with selenium sulfide 2.5% and ketoconazole 2% both beating placebo, but no single agent clearly superior within the class, and almost no trials assessing beyond 4 weeks, so long-term and maintenance efficacy is under-evidenced. (Okokon EO, Verbeek JH, Ruotsalainen JH, et al. "Topical antifungals for seborrhoeic dermatitis." Cochrane Database Syst Rev. 2015;(5):CD008138. Strong on the evidence-grading method — independent systematic review — but explicitly downgraded for short follow-up and within-class indistinguishability. The review is independent and flags that the underlying trials are mostly industry-funded and short.)

Chronicity — control, not cure (Strong; uncontested consensus).

6. Seborrheic dermatitis is chronic and relapsing; treatment relieves and reduces flares but does not cure, so maintenance is expected. Management targets are reducing Malassezia load, controlling inflammation, and restoring the barrier, not "fixing dryness." Stopping treatment tends to relapse. (Dall'Oglio F, Nasca MR, Gerbino C, Micali G. "An Overview of the Diagnosis and Management of Seborrheic Dermatitis." Clin Cosmet Investig Dermatol. 2022;15:1537–1548, and consistent across multiple reviews and guidelines. Strong — the control-not-cure framing is uncontested clinical consensus, with no material commercial conflict on the chronicity point.)

Mechanism

Why it is a yeast-and-sebum problem, not a dry scalp. Malassezia is a yeast that lives on virtually everyone's skin, concentrated where sebaceous glands are dense: scalp, face (the sides of the nose, eyebrows, the hairline), and upper chest. It is lipophilic and lipid-dependent. It cannot make its own long-chain fatty acids, so it lives off the lipids it finds, primarily the triglycerides in your sebum. Its lipases split those triglycerides into free fatty acids; it consumes the saturated ones it likes and leaves the unsaturated ones, notably oleic acid, behind. In a susceptible person, that accumulated oleic acid penetrates an already-leaky stratum corneum, triggers inflammation, and speeds up skin-cell turnover, which produces the flaking and the greasy, yellowish scale. So the substrate is an oily scalp with abundant sebum, not a dry one. Calling it "dry scalp" inverts the actual condition.

Why individual susceptibility matters. Everyone carries Malassezia, but not everyone flakes. The differentiator is sensitivity to the fatty-acid byproducts plus an impaired barrier that lets those byproducts through. Applying oleic acid directly to susceptible scalps reproduces the flaking even without the yeast present, which tells you the inflammation is partly about the host's reaction, not just the yeast count. This is why "kill all the yeast" is not quite the frame; "reduce the yeast and its irritating byproducts, and respect the barrier" is closer.

Why oils can feed the yeast. Because Malassezia depends on longer-chain fatty acids it cannot make itself, applying an oleic-rich oil provides exactly the substrate it favours. Olive oil is high in oleic acid (C18:1), the same fatty acid implicated in the flaking, so it is the worry. Coconut oil is the instructive exception: it is dominated by lauric acid (C12, a medium-chain fat), which lab studies report as growth-inhibitory against Malassezia rather than good fuel, so coconut is the poor-to-inhibitory substrate, not the one to fear on substrate grounds. The intuitive moisture-and-oil response, sensible for a genuinely dry scalp, can therefore hand a seborrheic scalp more fuel when the oil is oleic-rich. This is mechanistically well-grounded; what it is not is RCT-proven at the level of "olive oil makes seborrheic dermatitis worse." Hold it as a strong caution, not a settled harm, and note that medium-chain fats like the lauric acid in coconut are poor (even inhibitory) substrates, so a blanket "all oils are bad" overstates it.

Why antifungals work and why it relapses. Ketoconazole, zinc pyrithione, selenium sulfide, and ciclopirox all reduce the Malassezia load, and reducing the yeast reduces the byproducts that drive the inflammation, so symptoms reliably improve versus placebo. But the yeast is a normal resident; you are not eradicating it, you are suppressing it. Stop the antifungal and the population recovers, the byproducts return, and the flaking comes back. That is the biology behind "control, not cure" and behind maintenance dosing.

Risks And Contraindications

• Over-claiming the oils-backfire point is the central honesty hazard. The lipophilic mechanism and Malassezia's lipid-dependence are solid, but there is no RCT showing any oil worsens seborrheic dermatitis. Frame it as "heavy oleic-rich occlusive oils (e.g. olive oil) can feed the yeast and often backfire," not "proven to worsen," and acknowledge that not every lipid is a substrate — the medium-chain lauric acid in coconut oil is actually growth-inhibitory in lab studies — so a blanket "all oils bad" overstates it. Equally, do not flip to "coconut oil treats dandruff": that has no RCT either, and the proven lever is still the antifungal shampoo.
• Misclassifying seborrheic dermatitis as dry scalp leads to counterproductive treatment. Dry scalp is a real, separate entity that genuinely benefits from moisturising and less washing. The error is applying the dry-scalp playbook (oils, occlusives) to a yeast-driven oily-scalp condition. Get the classification right before choosing the treatment.
• Set the chronic-not-curable expectation explicitly. Even effective treatment relapses on stopping. People who expect a cure abandon maintenance and conclude "nothing works," when in fact the shampoo was working and needed continuing. The goal is durable control.
• See a clinician when it doesn't fit or doesn't respond. Seborrheic dermatitis can mimic or co-occur with psoriasis, eczema, and other dermatoses; sudden severe, widespread, or treatment-resistant seborrheic dermatitis, or a markedly inflamed scalp, warrants medical assessment. This entry does not cover systemic antifungals or topical steroids — those are clinician decisions, not self-treatment.
• Within-class superiority is over-stated by sponsors. The Cochrane review found no clear winner among the antifungal agents, so do not over-pay or over-commit on the basis of one brand's "superior" trial; the practical rule is "use whatever controls yours."

Controversy

Nature: a well-established core (the Malassezia-plus-sebum-plus-susceptibility mechanism and the antifungal-shampoo efficacy) sits alongside a softer applied claim (heavy oils feed the yeast and backfire) and a widely-misunderstood causal story (it is not a dry scalp or a hygiene problem). Commercial pressure pulls in opposite directions, which is the useful tell.

Position A — "Antifungal shampoos genuinely work and the mechanism is real." Seborrheic dermatitis is driven by Malassezia lipase hydrolysis of sebum into free fatty acids (notably oleic acid) that breach the barrier and trigger inflammation; ketoconazole, zinc pyrithione, selenium sulfide, and ciclopirox reduce the yeast load and reliably beat placebo. This is the control-the-yeast frame.
• Best evidence: the three-factor mechanistic model, the head-to-head ketoconazole-versus-zinc-pyrithione RCT, and an independent Cochrane review confirming the class beats placebo.
• Where it's wrong if pushed too far: claiming one agent is durably superior, or implying the shampoo cures rather than controls.

Position B — "The popular consumer framings are wrong on causation." It is not a dry-scalp problem (the scalp is oily and the sebum is the substrate), not a hygiene problem, and applying oleic-rich oils or heavy occlusives can backfire because the yeast is lipophilic and metabolises those longer-chain lipids. And it is chronic-relapsing, not curable, so the honest frame is ongoing yeast control.
• Best evidence: Malassezia's lipid-dependence and the oleic-acid mechanism; the uncontested chronic-relapsing consensus.
• Where it's wrong if pushed too far: "all oils are bad" overstates it (medium-chain fats like the lauric acid in coconut are poor-to-inhibitory substrates), and "oleic-rich oils worsen it" is mechanism-plus-consensus, not RCT-proven, so it should be a caution, not a verdict.

The funding/bias dimension — cui bono, both ways. Pulling toward "use our proven medicated shampoo": the dominant mechanistic model was largely built by Procter & Gamble Beauty scientists (DeAngelis, Schwartz, Dawson), and the major efficacy RCTs are manufacturer-sponsored (Janssen for ketoconazole, P&G for zinc pyrithione, selenium-sulfide makers), which favours within-class superiority claims. Pulling the other way: a large "natural / oil treatment" and "dry scalp" consumer-product economy — carrier-oil sellers, moisturising-shampoo brands, wellness influencers — profits from exactly the misframing this entry corrects, and the oils-backfire caution cuts against that economy. The independent Cochrane review confirms the antifungals beat placebo even after discounting sponsor framing, which is why the core "antifungal shampoos work" claim survives.

Realised Position: Both positions are true and they reinforce each other. Seborrheic dermatitis and dandruff are a Malassezia-plus-sebum-plus-individual-sensitivity inflammatory problem, so the move that works is reducing the yeast and its lipid byproducts with a proven antifungal shampoo used on a maintenance cadence — control, not cure — while avoiding the intuitive but counterproductive "my scalp is dry, add oil" response. Dry scalp is a genuinely different thing that does benefit from moisture; the error is misclassifying seborrheic dermatitis as dry scalp and then oiling it with an oleic-rich oil like olive oil, which can feed the yeast. Find an effective shampoo, use it regularly, expect relapse if you stop. The claim that benefits no seller — it's chronic, control it, see a doctor when it doesn't fit — has the cleanest evidence, which is the tell.

Cross-Pillar Connections

Seborrheic dermatitis is genuinely cross-pillar — a skin and scalp condition (physical/dermatology), an inflammatory response (immune), and a chronic-management problem that overlaps symptomatically with the other facial-skin conditions.
• Cross-pillar (evidence_based_minimal_skincare): owns the gentle-products, barrier-support, and minimalist-skincare reasoning this entry leans on but does not re-argue.
• Cross-pillar (acne_diet_lifestyle): the adjacent sebum-and-inflammation facial-skin condition; this entry holds the Malassezia/yeast framing and defers acne specifics there.
• Cross-pillar (rosacea_diet_and_lifestyle): another chronic, manage-not-cure facial condition with its own trigger and barrier story; shares the "control, not cure" and "harsh products backfire" logic, with a distinct mechanism.
• Cross-pillar (eczema_skin_barrier_lifestyle): the impaired-barrier dermatology entry; shares the barrier-breach reasoning, but eczema is barrier-and-immune driven rather than yeast-driven, so the treatment logic differs.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd soften the "oils backfire" position to neutral if a well-powered RCT directly comparing an oil or occlusive regimen against an antifungal shampoo (or against a no-oil control) showed oils do not worsen and possibly help seborrheic dermatitis.
• We'd change the "pick whatever works, no clear winner" framing if a long-term (6–12 month) head-to-head trial showed one antifungal class is durably superior in maintenance.
• We'd widen the entry beyond the yeast-control frame if evidence showed a meaningful subset of cases labelled seborrheic dermatitis is genuinely sebostatic dry scalp that resolves with emollients alone.
• We'd downgrade the individual-susceptibility mechanism if independent (non-P&G, non-manufacturer) replication failed to reproduce the oleic-acid-induced flaking in susceptible subjects.
• What would NOT move us: the antifungal-beats-placebo result (independent Cochrane confirmation) and the chronic-relapsing consensus are robust. Independent (non-seller) funding is the decisive variable; the cleanest signals are the ones sellers don't profit from.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs in both directions, which is why the least-conflicted signals are the anchors.
• The medicated-shampoo end: the dominant mechanistic model (Malassezia lipase → oleic acid → barrier breach → inflammation) was largely built by Procter & Gamble Beauty scientists (DeAngelis, Schwartz, Dawson, makers of Head & Shoulders), and the major efficacy RCTs are manufacturer-sponsored — Janssen for ketoconazole, P&G for zinc pyrithione, and selenium-sulfide makers. This funding favours "use our proven medicated shampoo" conclusions and within-class superiority claims.
• The natural / dry-scalp end: a large consumer-product economy — carrier-oil and coconut-oil sellers, moisturising and "soothing" shampoo brands, and wellness influencers selling the dry-scalp story — profits from exactly the misframing this entry corrects. The oils-backfire caution is the commercially unpopular position, which slightly raises its credibility as a non-self-serving correction, even though its trial base is thin.
• The clean signal: the most independent, most-replicated claim is the load-bearing one — an independent Cochrane review confirms the antifungals beat placebo even after discounting sponsor framing, and it is the same review that refuses to crown a within-class winner. The chronic-not-curable framing carries no material commercial conflict. The entry leans on those and walls both the sponsor-favoured "our shampoo is superior" claim and the influencer-favoured "just oil your dry scalp" claim.

Dandruff and Seborrheic Dermatitis: A Yeast-and-Sebum Problem, Not a Dry Scalp